cetuximab
Colorectal Cancers Dial up Mutability in Response to Targeted Treatments
A new study suggests that colorectal cancers increase their mutation rate to dodge treatment in a manner that mirrors microbial resistance mechanisms.
Keytruda and Ibrance demonstrate activity in molecularly defined populations, while a new cohort will explore Gilotrif in tumors with NRG1 fusions.
BioMarker Strategies Wins NCI Grant to Develop Head and Neck Cancer CDx
The company is developing a companion diagnostic to identify head and neck cancer patients most likely to benefit from Erbitux.
The results confirmed that circulating mutations can be reliably detected and changed during treatment, and showed that they could be a valuable prognostic biomarker.
Results from a recent study clarify some conflicting prior determinations, and provide a new rationale to further explore the FCGR2A biomarker in prospective trials.